Patients with thyroid cancer (TC) usually have an excellent prognosis; however, 5–10% of
them develop an advanced disease. The prognosis of this subgroup is still favourable if the …

Opinion Statement Radioiodine refractory differentiated thyroid cancer (RAI-R DTC) is a
challenging malignancy with limited prognosis and treatment options. Recently, clinical trials …

During the last decades the knowledge on follicular cell-derived thyroid cancer (TC)
molecular biology has led to the evolution of a number of novel therapies for these tumors …

The cumulative evidence over the past decades has shown that the incidence of
differentiated thyroid carcinoma (DTC) has exponentially increased. Approximately 10% of …

Background: The management of patients with locally advanced or metastatic differentiated
thyroid cancer (DTC) that is refractory to radioiodine (RAI) remains a therapeutic challenge …

Thyroid cancer is the single most prevalent endocrine malignancy; differentiated thyroid
cancer (DTC) accounts for more than 90% of all malignancies and its incidence has been …

Until recently, no truly effective treatment options have existed for patients with radioactive
iodine (RAI)-refractory differentiated thyroid cancer (DTC), a serious disease with poor …

Patients with differentiated thyroid cancer usually present with early-stage disease and
undergo surgery followed by adjuvant radioactive iodine ablation, resulting in excellent …

Approximately 90% of thyroid cancers are differentiated (DTCs) and have papillary, follicular
or Hürthle cell morphology. Although treatment with surgery and radioactive iodine (I-131; …

Notwithstanding regulatory approval of lenvatinib and sorafenib to treat radioiodine-
refractory differentiated thyroid carcinoma (RAI-R DTC), important questions and …